Bioxyne Reports Record Revenue, Yet Cash Outflows Climb on Expansion Push

SYDNEY – Bioxyne Limited, an Australian life sciences and wellness products company, posted its highest quarterly revenue on record for the period ended September 30, with sales reaching A$14.1 million, a 210% jump from the prior-year quarter and 47% above the previous three months.

The results signal robust demand in Europe and the United Kingdom, where the company shipped its first major order to a German partner and ramped up white-label offerings of Cannabis flower, vapes, and oils.

Still, the gains came at a cost. Operating cash flow swung to a A$4.1 million deficit, up sharply from the A$0.6 million outflow in the year-ago period, as Bioxyne poured resources into inventory and supply chain buildup. Payments to suppliers for manufacturing hit A$15.1 million, while staff and administrative expenses added another A$1.7 million combined. The company attributed much of the strain to a A$2.5 million bet on Cannabis flower stocks to fulfill anticipated European orders, pushing total inventory to A$6.1 million from A$3.6 million at June’s end.

On a brighter note, net cash rose A$7.7 million after factoring in A$1.2 million from borrowings and a modest A$0.25 million outlay for plant upgrades, including security infrastructure. Bioxyne now operates licensed facilities in Australia, the UK and Czechia, where it pursues EU-GMP certification to unlock broader continental sales.

The numbers reflect a company in full growth mode. Revenue from international markets, particularly a A$2.2 million initial shipment to Adrex Pharma in Germany [part of A$5.1 million in secured purchase orders] accounted for the bulk of the surge. Domestic Australian sales of pastilles and related items held steady, but executives highlighted regulatory tailwinds, including Germany’s recent Cannabis law reforms and potential U.S. rescheduling, as fresh opportunities.

Analysts tracking the sector see the cash pressures as par for the course in a capital-intensive field like medicinal Cannabis, where upfront stockpiling often precedes revenue spikes. If Bioxyne delivers on its full-year targets [A$65 million to A$75 million in sales and A$11.5 million to A$13.5 million in underlying earnings before interest, taxes, depreciation, and amortization] the quarter’s investments could pay off handsomely. Yet execution risks remain, especially with currency fluctuations and supply chain hiccups in cross-border trade.

To sum this quarter up, it underscores Bioxyne’s bet on the global scale: strong top-line momentum buoys investor confidence, but tightening the cash cycle will determine if the expansion sticks the landing. Investors should watch the next few months for signs that those German orders convert to repeat business and Czechia certification clears regulatory hurdles without delay.